American Association for Cancer Research
15417786mcr190638-sup-224202_2_supp_6180688_q7p1sy.pdf (192.72 kB)

Supplementary Table S1 from Growth-Inhibitory Activity of Bone Morphogenetic Protein 4 in Human Glioblastoma Cell Lines Is Heterogeneous and Dependent on Reduced SOX2 Expression

Download (192.72 kB)
journal contribution
posted on 2023-04-03, 17:00 authored by Erika Dalmo, Patrik Johansson, Mia Niklasson, Ida Gustavsson, Sven Nelander, Bengt Westermark

Table S1. Enriched GO terms for commonly upregulated genes in responsive cell lines and U3017MG harboring the control vector upon BMP4 treatment, according to the Database for Annotation, Visualization and Integrated Discovery (DAVID).


Swedish Research Council

Swedish Cancer Society

Swedish Foundation for Strategic Research

National Genomics Infrastructure

Swedish Research Council

Find out more...

Sweden and Science for Life Laboratory



Glioblastoma multiforme continues to have a dismal prognosis. Even though detailed information on the genetic aberrations in cell signaling and cell-cycle checkpoint control is available, no effective targeted treatment has been developed. Despite the advanced molecular defects, glioblastoma cells may have remnants of normal growth-inhibitory pathways, such as the bone morphogenetic protein (BMP) signaling pathway. We have evaluated the growth-inhibitory effect of BMP4 across a broad spectrum of patient samples, using a panel of 40 human glioblastoma initiating cell (GIC) cultures. A wide range of responsiveness was observed. BMP4 sensitivity was positively correlated with a proneural mRNA expression profile, high SOX2 activity, and BMP4-dependent upregulation of genes associated with inhibition of the MAPK pathway, as demonstrated by gene set enrichment analysis. BMP4 response in sensitive cells was mediated by the canonical BMP receptor pathway involving SMAD1/5/9 phosphorylation and SMAD4 expression. SOX2 was consistently downregulated in BMP4-treated cells. Forced expression of SOX2 attenuated the BMP4 sensitivity including a reduced upregulation of MAPK-inhibitory genes, implying a functional relationship between SOX2 downregulation and sensitivity. The results show an extensive heterogeneity in BMP4 responsiveness among GICs and identify a BMP4-sensitive subgroup, in which SOX2 is a mediator of the response. Development of agonists targeting the BMP signaling pathway in glioblastoma is an attractive avenue toward a better treatment. Our study may help find biomarkers that predict the outcome of such treatment and enable stratification of patients.